Patients with an actionable molecular biomarker or genomic tumor driver mutation mostly received TKIs, and patients with no actionable mutations and with PD-L1 TPS ≥50% mostly received PD-1/PD-L1 inhibitor monotherapy through the years. Here, CD274 is linked to neoplasm.